New car­dio tar­get ANGPTL3 with promis­ing new stud­ies; Liv­er­pool says Redx is delin­quent; Aslan's $33M Taipei IPO

→ Re­gen­eron and Io­n­is each have pub­li­ca­tions in The New Eng­land Jour­nal of Med­i­cine aimed at a brand new car­dio tar­get ANGPTL3. The New York Times chron­i­cles the sto­ry, which be­gins in 1994 when a woman in St. Louis gave a blood sam­ple at an em­ploy­er-spon­sored health fair.  Re­gen­eron is work­ing on a mon­o­clon­al an­ti­body which they say has re­duced ath­er­o­scle­rot­ic le­sions in mice and low­ered triglyc­erides and LDL in hu­mans. Io­n­is is go­ing af­ter the same tar­get us­ing an an­ti­sense oligonu­cleotide tar­get­ing Angptl3 mes­sen­ger RNA. They say they ob­served dose-de­pen­dent re­duc­tions in triglyc­erides and LDL, slow­ing of ath­er­o­scle­ro­sis pro­gres­sion and an in­crease in in­sulin sen­si­tiv­i­ty in mice that re­ceived the com­pound. Hu­man par­tic­i­pants who re­ceived week­ly in­jec­tions of the oligonu­cleotide had triglyc­eride re­duc­tions rang­ing from 33% to 63%, LDL re­duc­tions rang­ing from 1% to 33%, VLDL re­duc­tions of 28%-60%, and non-HDL lev­el re­duc­tions of 10% to 36.6%.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.